S&P Futures
4,198.75 +74.25 (+1.80%) Dow Futures
33,166.00 +429.00 (+1.31%) Nasdaq Futures
13,360.25 +328.75 (+2.52%) Russell 2000 Futures
1,950.30 +35.70 (+1.86%) Crude Oil
90.70 +0.20 (+0.22%) Gold
1,821.00 +8.70 (+0.48%)
Genprex, Inc. (GNPX)
- PR Newswire
Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that Company manufacturing leadership will present sessions on cutting edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit taking place from July 19-21, 2022 in Boston.
- PR Newswire
Genprex to Present at Upcoming June Investor Conferences
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in June 2022.
- PR Newswire
Genprex to Present at Upcoming Investor Conference in May 2022
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes to investors at the following conference in May 2022.
